Wellgistics Health, Inc. (NASDAQ: WGRX) Releases 2025 Annual Report: Key Details for Investors

Company Overview

Wellgistics Health, Inc., formerly Danam Health, Inc., is a holding company incorporated in 2022 and headquartered in Tampa, FL. The company operates a micro health ecosystem with a portfolio comprising pharmacy, wholesale operations, and a technology division focused on hub and clinical services. Its mission is to improve patient outcomes by integrating pharmaceuticals and healthcare services into a novel, tech-enabled platform.

Key Highlights from the Annual Report

• NASDAQ Listing: WGRX’s common stock, par value \$0.0001 per share, is registered on the NASDAQ Capital Market, providing increased visibility and access to capital markets for shareholders.
• Share Structure: As of March 6, 2026, there were 105,854,108 shares issued and 104,871,987 shares outstanding, indicating a minor portion held in treasury or unvested shares. The aggregate market value of voting and non-voting common stock held by non-affiliates was approximately \$27.1 million as of June 30, 2025.
• Emerging Growth and Smaller Reporting Company Status: WGRX is classified as both an emerging growth company and a smaller reporting company, enabling it to benefit from reduced regulatory burdens and potentially quicker growth cycles.
• Recent Acquisition: On August 30, 2024, Wellgistics Health closed the acquisition of Wellgistics LLC, expanding its wholesale operations to distribution and fulfillment of pharmaceuticals to independent pharmacies. The acquisition terms included:
  • \$10 million closing cash payment, with \$1 million payable to Zions Bank and the remainder due within 45 days of registration statement effectiveness or by August 30, 2025.
  • \$15 million promissory note, payable in three equal annual installments with interest at the Prime Rate.
  • Bonus payments in common stock totaling \$10 million, vesting over three years.
  • Additional \$5 million in common stock, vesting only if financial metrics are met (subject to repurchase at \$0.0001 per share if not achieved).
  • Contingent bonus payments (50% cash, 50% stock) if EBITDA exceeds 110% of targets for 2024, 2025, and 2026.
• Amendment to Acquisition Terms: On March 6, 2025, the company amended the acquisition terms to extend the due date for the \$10 million cash payment, aligning it with registration statement effectiveness or August 30, 2025.
• Technology Focus: The DelivMeds hub platform enables real-time, de-identified data dashboards for enterprise clients (e.g., Account Care Organizations, payors, health systems). Customizable reports assist partners in data mining, monitoring adherence, insurance coverage, and tracking dispositions.
• AI and Analytics: The company leverages AI and analytics to enhance medication adherence, HEDIS scores, and clinical reporting for providers, aiming to improve remuneration and patient outcomes.
• Risk Factors: Shareholders should note several risks disclosed, including:
  • Dependency on introduction of new brand/generic drugs and procurement costs.
  • Economic conditions affecting consumer adoption of the DelivMeds mobile app and premium services.
  • Reliance on primary wholesalers and manufacturer relationships.
  • Healthcare regulatory changes and competition.
  • Execution risks linked to business strategy and plan.
  • Uncertainties inherent in forward-looking statements and assumptions.
• Financial Reporting: The company has not restated financial results for error corrections, and no recovery analysis on incentive-based compensation for executives was required.
• Internal Controls: The report indicates no attestation to management’s assessment of internal controls under Section 404(b) of Sarbanes-Oxley, likely due to the company’s emerging growth/smaller reporting status.
• Forward-Looking Statements: The report contains extensive forward-looking statements regarding growth prospects, technology deployment, acquisitions, and financial targets, but cautions actual results may differ materially due to various risks and uncertainties.

Potential Price-Sensitive Information

• Acquisition of Wellgistics LLC: The successful integration and performance of Wellgistics LLC, including achievement of financial targets and EBITDA bonuses, could materially affect future revenue and profitability, potentially impacting share value.
• Delayed Cash Payment: Extension of the \$10 million closing payment may affect liquidity and risk profile. Investors should monitor for timely completion of payment obligations as per amended terms.
• Performance-Based Stock Awards: Issuance and vesting of substantial stock awards tied to achievement of financial metrics may affect dilution and share price, especially if targets are met or missed.
• Technology and AI Initiatives: Adoption and success of DelivMeds and related analytics platforms may drive future growth, but failure to achieve market penetration or regulatory hurdles could pose downside risks.
• Regulatory and Competition Risks: Changes in healthcare regulations, industry consolidation, and competitive dynamics may influence business outlook and share value.

Important Shareholder Information

• WGRX is NOT a shell company and has robust operations, including recent acquisition activity and technology development.
• The company’s public float is \$27.1 million, and the share count is substantial, which may impact liquidity and volatility.
• No documents are incorporated by reference in this annual report, and the company has not filed a transition report.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All forward-looking statements are subject to risks and uncertainties, and actual results may differ materially. Investors should review the full SEC filings and consult their financial advisors before making any investment decisions. The author assumes no responsibility for any investment actions taken based on this information.

View Wellgistics Health, Inc. Historical chart here